KLP Kapitalforvaltning AS Purchases 10,000 Shares of Recursion Pharmaceuticals, Inc. $RXRX

KLP Kapitalforvaltning AS increased its position in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 19.5% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 61,200 shares of the company’s stock after purchasing an additional 10,000 shares during the period. KLP Kapitalforvaltning AS’s holdings in Recursion Pharmaceuticals were worth $310,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. AlphaQuest LLC bought a new stake in shares of Recursion Pharmaceuticals during the 1st quarter valued at $36,000. GAMMA Investing LLC increased its holdings in Recursion Pharmaceuticals by 39.0% in the 1st quarter. GAMMA Investing LLC now owns 7,224 shares of the company’s stock valued at $38,000 after acquiring an additional 2,026 shares during the last quarter. Janney Montgomery Scott LLC bought a new stake in Recursion Pharmaceuticals in the 2nd quarter valued at $51,000. ADG Wealth Management Group LLC bought a new stake in Recursion Pharmaceuticals in the 1st quarter valued at $55,000. Finally, Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in Recursion Pharmaceuticals in the 1st quarter valued at $57,000. 89.06% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a report on Wednesday, October 8th. Morgan Stanley assumed coverage on shares of Recursion Pharmaceuticals in a report on Thursday, July 3rd. They issued an “equal weight” rating and a $5.00 price target on the stock. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $8.00 price target on shares of Recursion Pharmaceuticals in a report on Thursday, September 11th. Two research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $7.25.

Insider Buying and Selling

In related news, insider Najat Khan sold 36,599 shares of the company’s stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $5.52, for a total transaction of $202,026.48. Following the transaction, the insider directly owned 668,197 shares in the company, valued at approximately $3,688,447.44. This represents a 5.19% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 8.43% of the company’s stock.

Recursion Pharmaceuticals Stock Performance

Recursion Pharmaceuticals stock opened at $5.86 on Monday. The company’s 50-day moving average price is $5.13 and its 200-day moving average price is $5.13. Recursion Pharmaceuticals, Inc. has a twelve month low of $3.79 and a twelve month high of $12.36. The company has a quick ratio of 3.58, a current ratio of 3.58 and a debt-to-equity ratio of 0.02. The company has a market cap of $2.54 billion, a PE ratio of -3.29 and a beta of 0.91.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its earnings results on Tuesday, August 5th. The company reported ($0.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.06). Recursion Pharmaceuticals had a negative return on equity of 76.09% and a negative net margin of 1,004.91%.The business had revenue of $19.10 million during the quarter, compared to the consensus estimate of $15.38 million. During the same quarter last year, the firm earned ($0.40) earnings per share. The business’s quarterly revenue was up 33.3% on a year-over-year basis. On average, equities research analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current fiscal year.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.